BioCentury | Aug 11, 2020
Finance

AI play Atomwise to build internal pipeline with $123M series B

...preclinical cancer program against PIM3 as an example. Atomwise launched the JV in 2018 with Velocity Pharmaceutical Development...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

...to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development...
BioCentury | May 30, 2016
Company News

Astellas, Thunderbolt deal

...Vitesse last year -- Baxalta Inc. (NYSE:BXLT, Bannockburn, Ill.), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development LLC...
BioCentury | May 26, 2016
Company News

Vitesse launches first newco Thunderbolt

...the Baxter Ventures arm of Baxter International Inc. (NYSE:BAX), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development...
BioCentury | Jul 13, 2015
Strategy

Baxalta's blueprint

...which was created in June by Baxter's Baxter Ventures arm, the Mayo Clinic and Velocity Pharmaceutical Development LLC...
...Mass. Sigma-Tau Group, Pomezia, Italy U.S. Food and Drug Administration (FDA) , Silver Spring, Md. Velocity Pharmaceutical Development LLC...
BioCentury | Jun 8, 2015
Company News

Velocity Pharmaceutical Development, Vitesse Biologics, Baxter, Mayo Clinic deal

...details of the arrangement. Each Vitesse project will be housed in its own virtual company. Velocity Pharmaceutical Development LLC...
BioCentury | Jun 2, 2015
Company News

Baxter, Velocity, Mayo Clinic create Vitesse

...The Baxter Ventures arm of Baxter International Inc. (NYSE:BAX), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development...
BioCentury | Jan 5, 2015
Clinical News

Serlopitant: Phase II data

...tolerated. Patients received once-daily placebo or 0.25, 1 or 5 mg VPD-737 for 6 weeks. Velocity Pharmaceutical Development LLC...
BioCentury | Jun 30, 2014
Clinical News

Serlopitant: Phase II started

...created to develop VPD-737 (see BioCentury, Sept. 2, 2013). The virtual company is managed by Velocity Pharmaceutical Development...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...by VC firms include Atlas' Atlas Venture Development Corp. and Nimbus Discovery LLC , CMEA's Velocity Pharmaceutical Development LLC...
...San Francisco , San Francisco, Calif. University of California, Santa Cruz , Santa Cruz, Calif. Velocity Pharmaceutical Development LLC...
Items per page:
1 - 10 of 15
BioCentury | Aug 11, 2020
Finance

AI play Atomwise to build internal pipeline with $123M series B

...preclinical cancer program against PIM3 as an example. Atomwise launched the JV in 2018 with Velocity Pharmaceutical Development...
BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

...to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development...
BioCentury | May 30, 2016
Company News

Astellas, Thunderbolt deal

...Vitesse last year -- Baxalta Inc. (NYSE:BXLT, Bannockburn, Ill.), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development LLC...
BioCentury | May 26, 2016
Company News

Vitesse launches first newco Thunderbolt

...the Baxter Ventures arm of Baxter International Inc. (NYSE:BAX), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development...
BioCentury | Jul 13, 2015
Strategy

Baxalta's blueprint

...which was created in June by Baxter's Baxter Ventures arm, the Mayo Clinic and Velocity Pharmaceutical Development LLC...
...Mass. Sigma-Tau Group, Pomezia, Italy U.S. Food and Drug Administration (FDA) , Silver Spring, Md. Velocity Pharmaceutical Development LLC...
BioCentury | Jun 8, 2015
Company News

Velocity Pharmaceutical Development, Vitesse Biologics, Baxter, Mayo Clinic deal

...details of the arrangement. Each Vitesse project will be housed in its own virtual company. Velocity Pharmaceutical Development LLC...
BioCentury | Jun 2, 2015
Company News

Baxter, Velocity, Mayo Clinic create Vitesse

...The Baxter Ventures arm of Baxter International Inc. (NYSE:BAX), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development...
BioCentury | Jan 5, 2015
Clinical News

Serlopitant: Phase II data

...tolerated. Patients received once-daily placebo or 0.25, 1 or 5 mg VPD-737 for 6 weeks. Velocity Pharmaceutical Development LLC...
BioCentury | Jun 30, 2014
Clinical News

Serlopitant: Phase II started

...created to develop VPD-737 (see BioCentury, Sept. 2, 2013). The virtual company is managed by Velocity Pharmaceutical Development...
BioCentury | Mar 10, 2014
Finance

Innovator capital rationing

...by VC firms include Atlas' Atlas Venture Development Corp. and Nimbus Discovery LLC , CMEA's Velocity Pharmaceutical Development LLC...
...San Francisco , San Francisco, Calif. University of California, Santa Cruz , Santa Cruz, Calif. Velocity Pharmaceutical Development LLC...
Items per page:
1 - 10 of 15